Thomas Hedner
Department of Clinical Pharmacology
Sahlgrenska University Hospital
Göteborg
Sweden
Name/email consistency: high
- The evolution of ACE inhibition--a turning point in cardiovascular medicine. Hedner, T., Narkiewicz, K., Kjeldsen, S.E. Blood Press. (2007)
- The evolution of ACE inhibition--a turning point in cardiovascular medicine. Hedner, T., Narkiewicz, K., Kjeldsen, S.E. Blood. Press. Suppl (2007)
- Nabumetone: therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis. Hedner, T., Samulesson, O., Währborg, P., Wadenvik, H., Ung, K.A., Ekbom, A. Drugs (2004)
- The clinical profile of the angiotensin II receptor blocker eprosartan. Hedner, T. J. Hypertens. Suppl (2002)
- The problem of hypertension in the elderly. Hedner, T. Blood. Press. Suppl (2000)
- The efficacy and tolerance of one or two daily doses of eprosartan in essential hypertension. The Eprosartan Multinational Study Group. Hedner, T., Himmelmann, A. J. Hypertens. (1999)
- Management of hypertension: the advent of a new angiotensin II receptor antagonist. Hedner, T. J. Hypertens. Suppl (1999)
- Treating hypertension--effect of treatment and cost-effectiveness in respect to later cardiovascular diseases. Hedner, T. Scand. Cardiovasc. J. Suppl (1998)
- The early clinical history of salicylates in rheumatology and pain. Hedner, T., Everts, B. Clin. Rheumatol. (1998)
- Measures of endothelial function as an endpoint in hypertension?. Hedner, T., Sun, X. Blood. Press. Suppl (1997)